Literature DB >> 15856324

Cyclosporin A absorption profiles in children with nephrotic syndrome.

Kandai Nozu1, Kazumoto Iijima, Toshiyuki Sakaeda, Katsuhiko Okumura, Koichi Nakanishi, Norishige Yoshikawa, Masataka Honda, Masahiro Ikeda, Masafumi Matsuo.   

Abstract

A single blood concentration measurement of Neoral 2 h after administration (C2) is a new concept in therapeutic drug monitoring (TDM). In most adult patients, the concentration of cyclosporin A (CyA) peaks within 2 h after Neoral administration. Therefore, monitoring the area under the concentration-time curve over the first 4 h post-dose (AUC0-4) is considered to be the most reliable strategy for Neoral TDM. In addition, C2 is considered to be the most accurate predictor of AUC0-4, with which C2 correlates best. Thus, in adult patients, C2 monitoring is recommended as the best single-point TDM method for Neoral. However, in paediatric patients, the effectiveness of C2 monitoring is still unclear. We examined the trough concentration (C0), C1, C2, C3, and C4 of CyA in 60 patients (1 to 20 years old, mean age 7.42+/-0.67 years) who had nephrotic syndrome treated with Neoral. The peak concentration of C0-C4 was C1 or C2 in 38 patients (early peak group) and C3 or C4 in 22 patients (late peak group). C2 in the late peak group was significantly lower than that in the early peak group (422+/-50.1 vs. 665 +/-53.8 ng/ml, P =0.0008), although the administered doses of Neoral and C0 were similar between these groups. Therefore, TDM by C2 using the same standard as in the early peak group might result in an overdose of CyA in the late peak group. As the concentration peaked at 3 h or more after Neoral administration in the late peak group, AUC0-4 does not necessarily reflect the Neoral absorption profile. As more than 33% of the paediatric patients were in the late peak group, TDM by AUC0-4 or C2 should be used carefully in paediatric patients treated with Neoral.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15856324     DOI: 10.1007/s00467-005-1844-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  14 in total

Review 1.  Patient management by Neoral C(2) monitoring: an international consensus statement.

Authors:  Gary Levy; Eric Thervet; John Lake; Kazuharu Uchida
Journal:  Transplantation       Date:  2002-05-15       Impact factor: 4.939

2.  Recommendations for the implementation of Neoral C(2) monitoring in clinical practice.

Authors:  Edward Cole; Karsten Midtvedt; Atholl Johnston; James Pattison; Catherine O'Grady
Journal:  Transplantation       Date:  2002-05-15       Impact factor: 4.939

3.  Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study.

Authors:  Kamran Mahalati; Philip Belitsky; Kenneth West; Bryce Kiberd; Albert Fraser; Ingrid Sketris; Alan S Macdonald; Vivian McAlister; Joseph Lawen
Journal:  J Am Soc Nephrol       Date:  2001-04       Impact factor: 10.121

4.  Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation.

Authors:  E A Mueller; J M Kovarik; J B van Bree; W Tetzloff; J Grevel; K Kutz
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

5.  Oral cyclosporine pharmacokinetics in pediatric renal and liver transplant recipients.

Authors:  G F Cooney; S P Dunn; B Kaiser; A V Kulinsky; M Mochon; M Heifets
Journal:  Transplant Proc       Date:  1994-10       Impact factor: 1.066

Review 6.  Neoral use in the pediatric transplant recipient.

Authors:  S Dunn
Journal:  Transplant Proc       Date:  2000-05       Impact factor: 1.066

7.  Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection.

Authors:  Lutz T Weber; Victor W Armstrong; Maria Shipkova; Reinhard Feneberg; Manfred Wiesel; Otto Mehls; Lothar B Zimmerhackl; Michael Oellerich; Burkhard Tönshoff
Journal:  Ther Drug Monit       Date:  2004-08       Impact factor: 3.681

Review 8.  Factors influencing the pharmacokinetics of cyclosporine in man.

Authors:  A Lindholm
Journal:  Ther Drug Monit       Date:  1991-11       Impact factor: 3.681

9.  Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men.

Authors:  M S Shaefer; S J Rossi; T R McGuire; L J Schaaf; D S Collier; R J Stratta
Journal:  Ann Pharmacother       Date:  1995-11       Impact factor: 3.154

10.  Cyclosporine dosing and its relationship to outcome in pediatric renal transplantation.

Authors:  W E Harmon; E K Sullivan
Journal:  Kidney Int Suppl       Date:  1993-10       Impact factor: 10.545

View more
  8 in total

1.  Prediction of systemic exposure to cyclosporine in Japanese pediatric patients.

Authors:  Toshiyuki Sakaeda; Kazumoto Iijima; Kandai Nozu; Tsutomu Nakamura; Yuka Moriya; Mika Nishikawa; Atsushi Wada; Noboru Okamura; Masafumi Matsuo; Katsuhiko Okumura
Journal:  J Hum Genet       Date:  2006-09-14       Impact factor: 3.172

Review 2.  New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.

Authors:  Michael van Husen; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2011-01-13       Impact factor: 3.714

3.  Effectiveness and nephrotoxicity of a 2-year medium dose of cyclosporine in pediatric patients with steroid-dependent nephrotic syndrome: determination of the need for follow-up kidney biopsy.

Authors:  Yoshiyuki Kuroyanagi; Yoshimitsu Gotoh; Katsuaki Kasahara; China Nagano; Naoya Fujita; Satoshi Yamakawa; Masaki Yamamoto; Asami Takeda; Osamu Uemura
Journal:  Clin Exp Nephrol       Date:  2017-07-11       Impact factor: 2.801

4.  Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome.

Authors:  Katsumi Ushijima; Osamu Uemura; Takuji Yamada
Journal:  Eur J Pediatr       Date:  2011-11-26       Impact factor: 3.183

5.  Decreased cyclosporine exposure during the remission of nephrotic syndrome.

Authors:  Mara Medeiros; José Pérez-Urizar; Natalia Mejía-Gaviria; Eduardo Ramírez-López; Gilberto Castañeda-Hernández; Ricardo Muñoz
Journal:  Pediatr Nephrol       Date:  2006-10-20       Impact factor: 3.714

6.  Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study.

Authors:  Djalila Mekahli; Aurelia Liutkus; Bruno Ranchin; Anchalee Yu; Lucie Bessenay; Eric Girardin; Rita Van Damme-Lombaerts; Jean-Bernard Palcoux; François Cachat; Marie-Pierre Lavocat; Guylhène Bourdat-Michel; François Nobili; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2009-03-12       Impact factor: 3.714

7.  Correlation between finger-prick and venous ciclosporin levels: association with gingival overgrowth and hypertrichosis.

Authors:  Nicholas J A Webb; Malcolm G Coulthard; Richard S Trompeter; Margaret M Fitzpatrick; Suzanne Stephens; Jan Dudley; Heather Maxwell; Simon Waller; Graham C Smith; Alan R Watson; David A Hughes; Brian G Keevil; Janice S Ellis
Journal:  Pediatr Nephrol       Date:  2007-09-26       Impact factor: 3.714

8.  Pharmacokinetics of cyclosporin--a microemulsion in children with idiopathic nephrotic syndrome.

Authors:  Luciana dos Santos Henriques; Fabíola de Marcos Matos; Maria Helena Vaisbich
Journal:  Clinics (Sao Paulo)       Date:  2012-10       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.